A Phase I, Open Label, Multicenter, Parallel-group, Single Dose Two-staged Study to Evaluate the Pharmacokinetics and Safety of a Single 400 mg Oral Dose of LEE011 in Subjects With Varying Degrees of Impaired Renal Function Compared to Matched Healthy Volunteers With Normal Renal Function

Next Previous
Trial Profile

A Phase I, Open Label, Multicenter, Parallel-group, Single Dose Two-staged Study to Evaluate the Pharmacokinetics and Safety of a Single 400 mg Oral Dose of LEE011 in Subjects With Varying Degrees of Impaired Renal Function Compared to Matched Healthy Volunteers With Normal Renal Function

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Nov 2017

At a glance

  • Drugs Ribociclib (Primary)
  • Indications Breast cancer; Cancer; Liposarcoma; Lymphoma; Non-small cell lung cancer; Soft tissue sarcoma
  • Focus Pharmacokinetics
  • Sponsors Novartis Pharmaceuticals

    • Most Recent Events

    • 10 Nov 2017 Planned End Date changed from 30 Oct 2017 to 4 May 2018.
    • 08 May 2017 Planned End Date changed from 28 Apr 2017 to 30 Oct 2017.
    • 08 May 2017 Planned primary completion date changed from 13 Apr 2017 to 30 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top